

Trifluridine/Tipiracil (TAS-102) TAGS

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

OS

ADJUSTMENTS

Quality of life

No QoL benefit

Serious and disabling adverse effects

Other adjustments

Trifluridine/Tipiracil (TAS-102) TAGS

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

3

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
Therapeutic Indication: Metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, in patients who have been previously treated with ≥2 prior systemic treatment regimens for advanced disease
Experimental Arm: Trifluridine/Tipiracil (TAS-102)
Control Arm: Placebo



